Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E. coli bacteriophage Un
- Development stage
- Preclinical
- Lead developer
- George Eliava Institute of Bacteriophage, Microbiology and Virology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
E. coli bacteriophage Un is a lytic bacteriophage being developed by the G. Eliava Institute of Bacteriophages, Microbiology and Virology and the Agricultural University of Georgia for the treatment of Escherichia coli infections, including those caused by antibiotic-resistant and ESBL-producing strains. As a phage therapy, it specifically targets and infects E. coli bacteria, replicating within the host cells and ultimately causing bacterial lysis. Preclinical pharmacokinetic studies in mice have evaluated both purified and unpurified preparations of the phage administered via intravenous and subcutaneous routes, demonstrating systemic biodistribution, the ability to cross the blood-brain barrier, and stability in plasma and serum.
- Other names
- E. coli phage UnUn phage
Beyond the preview
Go deeper on E. coli bacteriophage Un.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E. coli bacteriophage Un.